Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin

Journal of Pharmaceutical Sciences

Volumn 97, Issue 6, 2008, Pages 2250-2259

  He, Weiling ^a   Jiang, Xuehua ^b   Zhang, Zhi Rong ^b  

^a UNIVERSITY OF WYOMING   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Bioavailability; Nanoparticles; Oral drug delivery; PBCA; Thymopentin

Indexed keywords

CYANOACRYLATE DERIVATIVE; NANOCARRIER; PHORBOL MYRISTATE; POLY(BUTYL 2 CYANOACRYLATE); THYMIDINE; THYMOPENTIN; TRITIUM; UNCLASSIFIED DRUG; DRUG CARRIER; ENBUCRILATE; IMMUNOLOGIC FACTOR; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRECIPITATION; RAT; SUSTAINED DRUG RELEASE; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CELL CULTURE; CHEMICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; FEASIBILITY STUDY; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; SOLUBILITY; SURFACE PROPERTY; T LYMPHOCYTE; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL PROLIFERATION; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; ENBUCRILATE; FEASIBILITY STUDIES; FEMALE; FLOW CYTOMETRY; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; MODELS, CHEMICAL; NANOPARTICLES; PARTICLE SIZE; PRECIPITATION; RATS; RATS, WISTAR; SOLUBILITY; SURFACE PROPERTIES; T-LYMPHOCYTES; TECHNOLOGY, PHARMACEUTICAL; THYMOPENTIN;

EID: 49249112430     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21148     Document Type: Article

References (37)

1. Wang J, Lu WL, Liang GW, Wu KC, Zhang CG, Zhang X, Wang JC, Zhang H, Wang XQ, Zhang Q. 2006. Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague-Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers. Peptides 27:826-835.
2. Zheng AP, Wang JC, Lu WL, Zhang X, Zhang H, Wang XQ, Zhang Q. 2006. Thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration: Preparation, characterization, and pharmacodynamics. J Nanosci Nanotechnol 6:2936-2944.
3. Zhang RL, Jiao Q, Wang BG. 2003. Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 23:654-657.
4. Giordano N, Biasi G, Taddeo A, Marcolongo R, Bertelletti D. 1989. An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis. Clin Rheumatol 8:293-294.
5. Goldstein G, Audhya TK. 1985. Thymopoietin to thymopentin: Experimental studies. Surv Immunol Res 4:1-10.
6. Greenhalgh D, Gamelli RL. 1987. Immunomodulators and wound healing. J Trauma 27:510-514.
7. Hamilton G, Zoch G, Rath T, Meissl G. 1989. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome. Prog Clin Biol Res 308:995-999.
8. Heavner GA. 1985. Thymopentin structure and relation to thymic factors. Surv Immunol Res 4:11-16.
9. Heavner GA, Audhya T, Goldstein G. 1990. Peptide analogs of thymopentin distinguish distinct thymopoietin receptor specificities on two human T cell lines. Regul Pept 27:257-262.
10. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C. 1997. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386:410-414.
11. Gomez-Orellana I. 2005. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2:419-433.
12. Pandey R, Ahmad Z, Sharma S, Khuller GK. 2005. Nano-encapsulation of azole antifungals: Potential applications to improve oral drug delivery. Int J Pharm 301:268-276.
13. Tao SL, Desai TA. 2005. Gastrointestinal patch systems for oral drug delivery. Drug Discov Today 10:909-915.
14. Bruschi ML, de FO. 2005. Oral bioadhesive drug delivery systems. Drug Dev Ind Pharm 31:293-310.
15. Bernkop-Schnurch A, Guggi D, Pinter Y. 2004. Thiolated chitosans: Development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J Control Release 94: 177-186.
16. Pandey R, Zahoor A, Sharma S, Khuller GK. 2003. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 83:373-378.
17. Li X, Zhu YF, Zhao MJ. 2003. The research on IR and TEM of polybutylcyanoacrylate nanoparticles. Guang Pu Xue Yu Guang Pu Fen Xi 23:266-269.
18. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, von BH. 2000. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 12:1931-1940.
19. Ratcliffe JH, Hunneyball IM, Smith A, Wilson CG, Davis SS. 1984. Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J Pharm Pharmacol 36:431-436.
20. Scherer D, Mooren FC, Kinne RK, Kreuter J. 1993. In vitro permeability of PBCA nanoparticles through porcine small intestine. J Drug Target 1: 21-27.
21. Shen LF, Zhang YD, Shen HJ, Zeng S, Wang X, Wang C, Le Y, Shen H. 2006. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice. Chin Med J (Engl) 119:1287-1293.
22. Sun X, Wu F, Lu W, Zhang ZR. 2004. Sustained-release hydroxycamptothecin polybutylcyanoacrylate nanoparticles as a liver targeting drug delivery system. Pharmazie 59:791-794.
23. He Q, Zhang Z. 1998. Determination of valaciclovir polybutylcyanoacrylate nanoparticles. Hua Xi Yi Ke Da Xue Xue Bao 29:272-274.
24. Katsikogianni G, Avgoustakis K. 2006. Poly(lactide-co-glycolide)-methoxy- poly(ethylene glycol) nanoparticles: Drug loading and release properties. J Nanosci Nanotechnol 6:3080-3086.
25. McCarthy JR, Perez JM, Bruckner C, Weissleder R. 2005. Polymeric nanoparticle preparation that eradicates tumors. Nano Lett 5:2552-2556.
26. Dong Y, Feng SS. 2005. Poly(D,L-lactide-co-glycolide)/ montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:6068-6076.
27. Garcia-Fuentes M, Torres D, Martin-Pastor M, Alonso MJ. 2004. Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles. Langmuir 20:8839-8845.
28. Santos MC, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schafer-Korting M. 2002. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 10:489-495.
29. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. 1999. Preparation and characterization of protein C-loaded PLA nanoparticles. J Control Release 60:179-188.
30. Page-Clisson ME, Pinto-Alphandary H, Ourevitch M, Andremont A, Couvreur P. 1998. Development of ciprofloxacin-loaded nanoparticles: Physicochemical study of the drug carrier. J Control Release 56:23-32.
31. Laszlo A, Petri I, Gyurkovits K. 1987. Spontaneous and stimulated lymphocyte transformation test in homozygous children with cystic fibrosis. Acta Paediatr Hung 28:101-105.
32. Koszinowski U, Volkmann B, Thomssen R. 1975. In-vitro demonstration of cell-mediated immunity to vaccinia virus in man. Z Immunitatsforsch Exp Klin Immunol 148:451-461.
33. Conti B, Panico M, Ventura CA, Giunchedi P, Puglisi G. 1997. Thymopentin loaded micro- sphere preparation by w/o/w emulsion technique: In vitro/ex vivo evaluation. J Microencapsul 14: 303-310.
34. Li LQ, Wang JX, Song DM, Fan SG, Mei L. 1996. Building up of an animal model of conditioned immunosuppression and analysis of its possible mechanism. Yao Xue Xue Bao 31:477-480.
35. He W, Zhang Z, Jiang X, Nie Y, Wu F. 2003. Stability evaluation of thymopentin in preparation process. Sichuan Da Xue Xue Bao Yi Xue Ban 34: 292-294.
36. Galvin F, Freeman GJ, Razi-Wolf Z, Hall W, Jr., Benacerraf B, Nadler L, Reiser H. 1992. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol 149:3802-3808.
37. Galvin F, Freeman GJ, Razi-Wolf Z, Benacerraf B, Nadler L, Reiser H. 1993. Effects of cyclosporin A, FK 506,and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. Eur J Immunol 23:283-286.